3 years ago

Biorelate Secures £6.5 Million Series A to Expand Drug Discovery AI Platform

  • Biorelate, a UK-based biotech company, has raised £6.5 million in Series A funding led by Maven Capital Partners and YFM Equity Partners

  • The funding will be used to expand the company's product, sales, and marketing departments, and establish operations in the US

  • Biorelate's AI platform, Galactic AI, uses natural language processing (NLP) and machine learning (ML) to capture valuable biomedical data for drug discovery

  • Since launching Galactic AI in 2020, Biorelate has worked with leading companies such as AstraZeneca and Idorsia.

      • ProblemTechnology

      "Drug discovery is a complex and time-consuming process, often hindered by the difficulty of accessing and analyzing relevant biomedical data."

      Solution

      "Biorelate's Galactic AI platform uses AI to curate and analyze large volumes of biomedical data, making it easier for pharmaceutical and life sciences companies to identify potential drug candidates and accelerate their drug discovery programs."

      Covered on